Interleukin-7
Trials 29
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00684008 | Mar 2008 → Apr 2011 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | Cytheris SA | Completed | No outcome recorded |
| Phase 1 | NCT00477321 | May 2007 → Oct 2009 | HIV infectious disease, lymphopenia | Cytheris SA | Completed | No outcome recorded |
| Phase 1 | NCT00492440 | May 2007 → Jul 2010 | cutaneous melanoma, kidney cancer | Cytheris SA | Terminated | No outcome recorded |
| Phase 1 | NCT00099671 | Apr 2005 → Apr 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00091338 | Aug 2004 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/27 trials · 1 met primary | ||||||
| Phase 1/2 | NCT03600896 | Nov 2018 → Nov 2023 | — | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01027065 | Dec 2009 → Nov 2012 | chronic hepatitis B virus infection | Cytheris SA | Unknown | No outcome recorded |
| Phase 1/2 | NCT00839436 | Feb 2009 → May 2014 | idiopathic CD4-positive T-lymphocytopenia | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/2 | NCT01024894 | Jan 2009 → Nov 2012 | chronic hepatitis C virus infection | Cytheris SA | Unknown | No outcome recorded |
| Phase 1/2 | NCT01025297 | Jul 2008 → Dec 2012 | chronic hepatitis C virus infection | Cytheris SA | Unknown | No outcome recorded |
| Phase 1/2 | NCT00923351 | Jun 2007 → Aug 2012 | alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, neuroblastoma, peripheral primitive neuroectodermal tumor | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1/2 | NCT01025596 | May 2007 → Feb 2011 | hepatitis C virus infection | Cytheris SA | Completed | No outcome recorded |
| Phase 217 trials · 7 missed | ||||||
| Phase 2 | NCT07308886 | Apr 2026 → Jan 2036 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04927169 | Mar → Dec 2021 | COVID-19, lymphopenia | Revimmune | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04426201 | Dec 2020 → Jun 2022 | COVID-19, lymphopenia | Revimmune | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04154826 | Nov 2020 → Dec 2023 | pulmonary non-tuberculous mycobacterial infection | Revimmune | Terminated | Missed primary |
| Phase 2 | NCT04442178 | Sep 2020 → Mar 2022 | COVID-19, lymphopenia | Revimmune | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04407689 | Jun 2020 → Mar 2022 | COVID-19, lymphopenia | Revimmune | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT04379076 | May 2020 → Feb 2022 | COVID-19, lymphopenia | Revimmune | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT03513952 | Jun 2019 → Sep 2023 | bladder transitional cell carcinoma, renal pelvis urothelial carcinoma, ureter transitional cell carcinoma, urethra transitional cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03821038 | Jun 2019 → Oct 2021 | infectious disease with sepsis | Revimmune | Terminated | No outcome recorded |
| Phase 2 | NCT03929107 | Mar 2019 → Jan 2022 | lymphoma | Wenbin Qian | Unknown | No outcome recorded |
| Phase 2 | NCT02797431 | Jan 2016 → Mar 2017 | infectious disease with sepsis | University Hospital, Limoges | Terminated | No outcome recorded |
| Phase 2 | NCT02640807 | Jan 2016 → Aug 2018 | infectious disease with sepsis | Revimmune | Completed | No outcome recorded |
| Phase 2 | NCT01368107 | Jun 2011 → Sep 2013 | breast cancer | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT01339000 | Apr 2011 → Apr 2016 | breast cancer, colon carcinoma, urinary bladder cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01019551 | Sep 2010 → Jul 2012 | HIV infectious disease | Objectif Recherche Vaccins SIDA | Completed | Missed primary |
| Phase 2 | NCT01241643 | Sep 2010 → Jun 2013 | HIV infectious disease | Cytheris SA | Terminated | No outcome recorded |
| Phase 2 | NCT01190111 | Jan 2010 → Jun 2013 | HIV infectious disease | Cytheris SA | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-12 | Selecxine | Results rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors selecxine.com ↗
Our data demonstrate that the combination of rhIL-7-hyFc and hIL-2/TCB2c increases efficacy and generates an immune-stimulatory tumor microenvironment (TME). |
All press releases naming this drug 1 release
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interleukin-7 | “A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in...” NCT01241643 ↗21“This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in HBeAg-negative chronic hepatitis B infected adult patients.” NCT01027065 ↗ “The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.” NCT00099671 ↗ “Interleukin-7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes.” PMID 19380868 ↗ Apr 2009 “Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells.” NCT00839436 ↗ “Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma” NCT07308886 ↗ “Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection” NCT01339000 ↗ “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ |
| Known as | CYT107 | “This is a Phase I inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in adult patients infected by Genotype 1 Virus of Hepatitis C and...” NCT01025596 ↗16“This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107) in adult patients infected by virus genotype 1 or 4 of Hepatitis C...” NCT01025297 ↗ “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗ “Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma” NCT03513952 ↗ “This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of Interleukin-7 (CYT107)” NCT01024894 ↗ “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ “CYT107 (r-hIL-7)” NCT00492440 ↗ |
| Known as | Glyco-r-hIL-7 | “A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in...” NCT01027065 ↗2“A PHASE I/IIa DOSE ESCALATION STUDY IN ASIA OF REPEATED ADMINISTRATION OF "CYT107" (Glyco-r-hIL-7) ADDED ON TREATMENT IN GENOTYPE 1 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED...” NCT01025596 ↗ “A Phase I/IIa Dose Escalation Study of Repeated Administration of "CYT107" (Glyco-r-hIL-7) Add-On Treatment in Genotype 1 or 4 Hcv Infected Patients Resistant to Pegylated...” NCT01025297 ↗ |
| Known as | Glyco-Recombinant Human IL-7 | “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗ |
| Known as | IL-7 | “A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7(CYT107) in Older Subjects...” NCT01339000 ↗8“METHODS: We conducted a prospective, double-blind, randomized, placebo-controlled trial of CYT107, recombinant human IL-7, in 109 critically ill, patients with lymphopenia who...” PMID 39903535 ↗ Feb 2025 “Determine the maximum tolerated dose of interleukin-7 (IL-7) when administered with melanoma peptide vaccine emulsified in Montanide ISA-51 in patients with metastatic melanoma.” NCT00091338 ↗ “The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.” NCT00099671 ↗ “Interleukin-7 (IL-7) is a common gamma chain receptor cytokine implicated in thymopoiesis and in peripheral expansion and survival of T lymphocytes.” PMID 19380868 ↗ Apr 2009 “Animal studies have shown that an experimental drug Interleukin 7 (IL-7), which is named CYT107, can increase the number and function of T cells.” NCT00839436 ↗ “This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.” NCT01025596 ↗ “parenteral administration of recombinant Interleukin-7 (IL-7) (CYT107)” NCT04154826 ↗ “Interleukin-7 (IL-7) is an antiapoptotic common γ-chain cytokine” PMID 29515037 ↗ Mar 2018 |
| Known as | Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03929107 ↗ |
| Known as | r-hIL-7 | “Recombinant human interleukin-7 (rhIL-7) may play a role in immune reconstitution and immune enhancement in various circumstances of immune insufficiency in older individuals...” NCT01339000 ↗7“Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period.” PMID 19287090 ↗ Mar 2009 “single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration.” PMID 26908786 ↗ Feb 2016 “The safety and activity of recombinant human IL-7 (rhIL-7) administration were therefore examined in HIV-infected persons.” PMID 19380868 ↗ Apr 2009 “We performed a phase 1 trial of r-hIL-7 (CYT107) in recipients of T-cell depleted allo-HSCTs.” PMID 23012326 ↗ Sep 2012 “recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose” NCT01019551 ↗ “CYT107 (r-hIL-7)” NCT00492440 ↗ |
| Known as | Recombinant Glycosylated Human Interleukin-7 | “Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma” NCT07308886 ↗ |
| Known as | Recombinant hIL-7 | “Recombinant hIL-7 induced CD4 and CD8 T cells to enter cell cycle;” PMID 19380868 ↗ Apr 2009 |
| Known as | recombinant human IL-7 | “Patients received a total of 8 subcutaneous injections of 2 different doses of recombinant human IL-7 (rhIL-7; 3 or 10 microg/kg) 3 times per week over a 16-day period.” PMID 19287090 ↗ Mar 20092“A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma” NCT03513952 ↗ “recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7))” NCT00923351 ↗ |
| Known as | Recombinant human interleukin-7 | “single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration.” PMID 26908786 ↗ Feb 20162“Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.” PMID 23012326 ↗ Sep 2012 “recombinant human IL-7 (interleukin 7) (rhIL-7 (recombinant human interleukin 7))” NCT00923351 ↗ |
| Known as | Recombinant Interleukin-7 | “A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in...” NCT01241643 ↗ |
| Action | Restore | “a single cycle of 3 weekly subcutaneous (s/c) injections of recombinant human interleukin 7 (r-hIL-7) is safe and improves immune CD4 T-cell restoration” PMID 26908786 ↗ Feb 2016 |
| Modality | Protein / enzyme biologic | “This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in...” PMID 16699374 ↗ May 2006 |
| Route | Subcutaneous | “Patients receive IL-7 subcutaneously (SC) on days 0, 3, 6, 9, 12, 15, 18, and 21.” NCT00091338 ↗ |